FDA wants to increase Number of foreign Inspections
Recommendation

14/15 October 2026
Vienna, Austria
Quality Oversight of Pharmaceutical Contract Manufacturing Organisations
In its proposed fiscal 2015 budget, the U.S. Food and Drug Administration FDA details the plans for their inspections in the new fiscal year. The agency would like to perform approx. 20 percent more foreign GMP inspections, from 827 in the year 2013 up to 999 in 2014 and 2015. The companies will be inspected based on a risk-based inspection model taking into account for example Class I recalls, adverse events and the compliance history.
FDA prioritises inspections at high-risk domestic and foreign companies. As a result, "in FY 2013 FDA has met or exceeded inspection targets for human drugs facilities". In the fiscal year 2013, 443 domestic and 365 foreign high-risk drug establishments have been inspected, 43 GMP-based Warning Letters were issued.
The total number of inspections in the U.S. will stay almost consistent, with a decrease of Drug Processing (GMP) Program Inspections from 967 to 591. The number of Pre-approval Inspections (PAI) and Adverse Drug Events Project Inspections will increase.
Source: Department of Health and Human Services Fiscal Year 2015 Justification of Estimates for Appropriations Committees
Related GMP News
16.09.2026How GMP Non-Compliance can stop a Marketing Authorisation Application
10.09.2026FDA Warning Letter: Inadequate Warehouse Controls and Lot Traceability
09.09.2026Specified Microorganisms and More - FDA Warning Letter
02.09.2026Deficiencies in Staffing, Monitoring and Aseptic Techniques – Warning Letter to a European Company
19.08.2026Poor Hygiene and Environmental Conditions - FDA Warning Letter


